Stapled scFv Antibody Fragments for CD3 Binding Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific antibodies that recruit cytolytic T cells to kill tumor cells face challenges such as unfavorable pharmacokinetics, potential immunogenicity, and manufacturing issues, limiting their clinical use.
Innovation Solution
Development of stapled single-chain variable fragments (spFv) that specifically bind to CD3ε, incorporating a variable heavy chain sequence, a variable light chain sequence, and a linker with cysteine residues to form disulfide bonds, enhancing stability and binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional scFv are used in bispecific antibodies, then manufacturing and pharmacokinetics are simplified, but stability and aggregation resistance are poor
Solution Approach 1:
The patent introduces stapled scFv (spFv) molecules with modified structural parameters compared to conventional scFv. The spFv incorporates a disulfide bond between the linker and the variable regions, creating a stabilized structure that resists aggregation while maintaining the simplified single-chain architecture. This parameter change in molecular structure directly addresses the stability issue without significantly increasing manufacturing complexity.
2Reliability
If bisspecific antibodies are designed to recruit cytolytic T cells, then tumor cell killing efficacy is improved, but toxicity and immunogenicity increase
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of the bispecific antibody through the use of spFv molecules. The stabilized structure of spFv reduces aggregation and improves half-life, which can enhance efficacy while reducing off-target effects and toxicity. The modified structure allows for optimized binding affinity and reduced immunogenicity, thereby improving the safety profile while maintaining tumor cell killing efficacy.
3Ease of manufacture
If conventional scFv are used, then manufacturing is easier, but aggregation tendency is high and stability is low
Solution Approach 1:
The patent introduces a disulfide bond in the linker region of the scFv molecule, creating a stabilized structure that reduces aggregation. This parameter change in the molecular structure enhances stability without significantly complicating the manufacturing process, as the spFv can still be produced using conventional recombinant DNA techniques. The stabilized structure maintains ease of manufacture while dramatically improving stability and reducing aggregation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stapled spFv antibodies demonstrate improved stability, reduced aggregation, and enhanced binding specificity to CD3, potentially leading to more effective recruitment of cytolytic T cells to tumor cells with reduced toxicity and improved manufacturing profiles.
Implementation Method 1
the Linker comprises at least one cysteine residue (Cys) that serves as an anchor point... the spFv comprises a disulfide bond between a surface exposed cysteine residue on at least one of the VH and VL the anchor point of the Linker
Data Source
AI summary
Stabilized CD3 antigen binding agents and methods of use thereof are disclosed.